Data Provided by Refinitiv. Minimum 15 minutes delayed.

Immunovaccine Receives Conditional Approval to Graduate to Toronto Stock Exchange (TSX)

November 12, 2014 at 12:00 AM EST

Shares to be Listed Under Symbol “IMV” on Canada’s Senior Stock Exchange 

Halifax, Nova Scotia; November 12, 2014 — Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX Venture: IMV), a clinical stage vaccine and immunotherapy company, today announced it has received conditional approval from Toronto Stock Exchange (“TSX”) to graduate from TSX Venture Exchange and list its common shares (the “Common Shares”) on TSX. 

“Over the past several quarters, Immunovaccine has made significant progress in advancing our broad pipeline of next-generation vaccine candidates in the areas of cancer and infectious diseases,” said Dr. Marc Mansour, chief executive officer of Immunovaccine.  “Our graduation to the main board is an important step as we broaden our investor audiences both in Canada and abroad.”

Final approval of the listing is subject to Immunovaccine meeting certain standard requirements of TSX. Immunovaccine expects to satisfy all of the requirements and will make a further announcement once TSX has issued a bulletin confirming the date on which trading on TSX will commence. Upon its listing on TSX, the Common Shares will continue to trade under the symbol “IMV”.

In connection with the listing on TSX, the Company will apply to voluntarily delist its Common Shares from TSX Venture Exchange. Such delisting will be effective as of the date the Common Shares commence trading on TSX.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer), with Immunovaccine also exploring additional studies in other indications including lymphoma and recurrent ovarian cancer. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.

Connect at

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Dr. Marc Mansour, Chief Executive Officer, Immunovaccine Inc.

T: (902) 492-1819 E:

Tim Brons, Vida Strategic Partners (media)

T: (415) 675-7402 E: